Horizon Therapeutics plc Announces Chief Financial Officer Succession Plan

Rhea-AI Summary

Horizon Therapeutics plc (Nasdaq: HZNP) announced the retirement of CFO Paul Hoelscher effective May 16, 2022, with Aaron Cox succeeding him. Hoelscher has been with Horizon since 2014, playing a crucial role in the company's growth. Cox, who joined Horizon in 2016, has led various strategic initiatives, including the Viela Bio acquisition. His extensive experience in corporate development and finance is expected to support Horizon's long-term strategy. Forward-looking statements regarding executive transitions and business growth were included, highlighting possible risks and uncertainties.

Positive

• Aaron Cox has been appointed CFO, bringing valuable experience from previous roles.
• Cox's background includes leadership in capital markets and strategic initiatives.

Negative

• None.

DUBLIN--(BUSINESS WIRE)-- Horizon Therapeutics plc (Nasdaq: HZNP) today announced Paul Hoelscher, executive vice president, chief financial officer, will retire effective May 16, 2022, and continue as an advisor to the Company through May 2023. Aaron Cox, who was named executive vice president, finance, will succeed Mr. Hoelscher.

“Paul has served as Horizon’s CFO since 2014 and has been critical in guiding and driving our growth,” said Tim Walbert, chairman, president and chief executive officer, Horizon. “He has built a strong finance team during his tenure and has been a valued partner to me and Horizon’s board of directors. I would like to thank him for his leadership as well as his dedication and commitment to Horizon’s mission.”

Walbert continued, “Aaron has been deeply involved in key aspects of our business during the last five years, including leading our capital markets activities. Additionally, he has been a leader in many of our major strategic efforts, including the Viela Bio acquisition. His experience at Horizon and his deep financial knowledge will be essential in continuing to drive our long-term strategy.”

Mr. Cox joined Horizon in 2016 and has served in various roles across business development and corporate development, including most recently as senior vice president, corporate development and chief of staff to Mr. Walbert, where he had responsibilities spanning financial planning, corporate strategy, mergers and acquisitions, acquisition integration and corporate project management. Additionally, he leads capital markets activities and oversees Horizon’s global real estate, security and facilities functions. Mr. Cox also previously spent time on Horizon’s business development team, where he supported multiple acquisitions, financings and licensing transactions. Before joining Horizon, Mr. Cox was vice president, capital markets at BMO Capital Markets and held investment banking roles at JMP Securities and Stout.

Mr. Cox earned a Master of Business Administration with concentrations in accounting, finance and economics from the University of Chicago Booth School of Business and a Bachelor of Business Administration in finance from the University of Notre Dame.

About Horizon

Horizon is focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, please visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.

Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to anticipated executive officer transitions and future growth of Horizon’s business. These forward-looking statements are based on Horizon’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, those risks detailed from time-to-time under the caption “Risk Factors” and elsewhere in Horizon’s filings and reports with the SEC. Horizon undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211103005390/en/

Tina Ventura

Senior Vice President, Investor Relations

Investor-relations@horizontherapeutics.com



Ruth Venning

Executive Director, Investor Relations

Investor-relations@horizontherapeutics.com



U.S. Media Contact:

Geoff Curtis

Executive Vice President, Corporate Affairs and Chief Communications Officer

media@horizontherapeutics.com

Ireland Media Contact:

Gordon MRM

Ray Gordon

ray@gordonmrm.ie

Source: Horizon Therapeutics plc

FAQ

When will Paul Hoelscher retire from Horizon Therapeutics?

Paul Hoelscher will retire effective May 16, 2022.

Who will succeed Paul Hoelscher as CFO of Horizon Therapeutics?

Aaron Cox will succeed Paul Hoelscher as CFO.

What role did Aaron Cox have before becoming CFO of Horizon Therapeutics?

Aaron Cox served as executive vice president, finance before becoming CFO.

What significant acquisition was Aaron Cox involved in at Horizon Therapeutics?

Aaron Cox played a key role in the acquisition of Viela Bio.

What are the forward-looking statements mentioned in Horizon Therapeutics' press release?

The press release includes statements about executive transitions and anticipated business growth, along with associated risks.